dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Razi, E. D. | en |
dc.contributor.author | Economopoulos, T. | en |
dc.contributor.author | Pectasides, Dimitrios | en |
dc.contributor.author | Gogas, H. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Klouvas, G. D. | en |
dc.contributor.author | Kyratzis, G. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Razi, E. D. | en |
dc.creator | Economopoulos, T. | en |
dc.creator | Pectasides, Dimitrios | en |
dc.creator | Gogas, H. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Klouvas, G. D. | en |
dc.creator | Kyratzis, G. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.date.accessioned | 2018-06-22T09:53:12Z | |
dc.date.available | 2018-06-22T09:53:12Z | |
dc.date.issued | 2005 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41711 | |
dc.description.abstract | Background: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory advanced epithelial ovarian cancer (AEOC). Patients and Methods: Patients (pts), who had been treated with platinum or paclitaxel and met the criteria of resistant/refractory AEOC, received GEM 650 mg/m2 days 1 and 8 and PLD 25 mg/m2 day 1 every 4 weeks up to a total of 6 cycles, unless disease progression or adverse effects prohibited further therapy. Results: Thirty-seven patients entered the study. There was 1 complete (3%) and 7 partial responses (19%) for an overall response rate of 22%. Two patients had stable disease (5.5%). After a median follow-up of 16.2 months, the median survival was 8.4 months and time to treatment failure 2.7 months. The most frequent severe toxicity was myelosuppression recorded in 13 (35%) patients. Severe stomatitis was recorded in only 2 (5%) cases and severe palmar-plantar erythrodysesthesia in 1 patient. One severe allergic reaction (grade 4) to PLD was recorded following the third cycle of treatment. Conclusion: The combination of GEM and PLD in patients with AEOC, who are resistant/refractory to platinum and/or Taxanes, did not show any superiority over monotherapy. However, in view of the acceptable toxicity profile, the above combination may deserve further investigation in a randomised setting. | en |
dc.language.iso | eng | en |
dc.source | Anticancer Research | en |
dc.subject | Article | en |
dc.subject | Doxorubicin | en |
dc.subject | Human | en |
dc.subject | 80 and over | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer survival | en |
dc.subject | Drug response | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm | en |
dc.subject | Ovarian cancer | en |
dc.subject | Ovarian neoplasms | en |
dc.subject | Ovary cancer | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Arthralgia | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Constipation | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Drug resistance | en |
dc.subject | Drug resistance | en |
dc.subject | Fatigue | en |
dc.subject | Leukopenia | en |
dc.subject | Myalgia | en |
dc.subject | Neurotoxicity | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Stomatitis | en |
dc.subject | Taxane derivative | en |
dc.subject | Taxoids | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Nephrotoxicity | en |
dc.subject | Platinum | en |
dc.subject | Drug administration schedule | en |
dc.subject | Drug fatality | en |
dc.subject | Fever | en |
dc.subject | Pain | en |
dc.subject | Disease course | en |
dc.subject | Clinical feature | en |
dc.subject | Organoplatinum compounds | en |
dc.subject | Vomiting | en |
dc.subject | Nausea | en |
dc.subject | Drug withdrawal | en |
dc.subject | Esophagitis | en |
dc.subject | Deoxycytidine | en |
dc.subject | Gemcitabine | en |
dc.subject | Pegylated liposomal doxorubicin | en |
dc.subject | Hand foot syndrome | en |
dc.subject | Cancer resistance | en |
dc.subject | Allergic reaction | en |
dc.subject | Treatment failure | en |
dc.subject | Multiple | en |
dc.subject | Lung injury | en |
dc.subject | Agranulocytosis | en |
dc.subject | Skin defect | en |
dc.title | Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 25 | |
dc.description.issue | 4 | |
dc.description.startingpage | 3103 | |
dc.description.endingpage | 3108 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |
dc.gnosis.orcid | 0000-0002-3286-778X | |